


VOL.  
18  
1984



Official Publication of the  
Drug Information Association



**PERGAMON PRESS**

New York • Oxford • Toronto • Paris • Frankfurt • Sydney

---

# DRUG INFORMATION JOURNAL

Official Publication of the Drug Information Association

---

## EDITOR-IN-CHIEF

**Thomas W. Teal**

*Director, Scientific Data Management  
McNeil Pharmaceutical*

## EDITORIAL BOARD

*Term ends December 31, 1984*

Joseph Hirschman, PhD, *American Druggist Blue Book Data Center*  
Harry Salem, PhD, *Toxicogenics*  
Hazel Seaba, *University of Iowa*  
Winifred Sewell, PhD, *Consultant*  
Jean Weston, MD, *Consultant*

*Term ends December 31, 1985*

Robert V. Cuddihy, *Oxford Research International*  
Edward Dietrich, *Merck, Sharp & Dohme*  
Saul L. Gitomer, *Marion Laboratories*  
Richard A. Guarino, MD, *Oxford Research International*  
Daniel Hussar, PhD, *Philadelphia College of Pharmacy & Science*  
Judith K. Jones, MD, PhD, *US Food and Drug Administration*  
Charles Leighton, MD, *Merck, Sharpe & Dohme*  
Patricia M. O'Brien, *Pharmaceutical Manufacturers Association*  
Peter H. Rheinstein, MD, JD, *US Food and Drug Administration*  
Arthur Wykes, PhD, *National Library of Medicine*

---

**Editorial Office:** Editor-in-Chief, *Drug Information Journal*, P.O. Box 113, Maple Glen, PA 19002, USA.

**Publishing, Subscription, and Advertising Offices:** Pergamon Press, Inc., Fairview Park, Elmsford, NY 10523, USA; or Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, England.

**Published quarterly.** Annual subscription rate (1985): US\$70.00; Two-year rate (1985/86): US\$133.00. Back issue and microform subscription information available upon request. All prices include surface postage and insurance; airmail subscriptions extra.

**Drug Information Association** members receive the *Drug Information Journal* as part of their annual dues. The Association is dedicated to the extension of modern technology in biomedical information and data processing as well as the encouragement of cooperative efforts among education, research, industrial and government personnel to disseminate information of that type. For information concerning membership, please write to: Drug Information Association, P.O. Box 113, Maple Glen, PA 19002  
Copyright © 1984 Drug Information Association Inc. Printed in the USA

**Copyright Notice:** It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher, if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise without permission in writing from the copyright holder.

**Photocopying information for users in the U.S.A.:** The Item-Fee Code for this publication indicates that authorization to photocopy items for the internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of \$3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

The Item-Fee Code for this publication is: 0092-8615/84 \$3.00 + .00

## Contents Volume 18, 1984

---

Volume 18, Number 1

1984

### CONTENTS

- |   |    |   |
|---|----|---|
| <b>Patricia Carty</b>   | 1  | About This Issue  |
| <b>Charles L. Bernd</b>   | 3  | Clinical Case Report Forms Design –<br>A Key to Clinical Trial Success                            |
| <b>Larry Kowitt</b><br><b>Robert L. Marlin</b>                                  | 9  | A Comprehensive On-Line<br>Collection System  |
| <b>Doron Steger</b>   | 15 | Use of the Microcomputer in a Clinical<br>Research Environment                                    |
| <b>Carol Lambros</b>  | 19 | The Evolution of a SAS Database   |
| <b>Stephen Ehrlich</b>  | 25 | User Friendly Applications to Clinical<br>Study Databases and Data Access                         |
| <b>Leaming J. Gandy</b><br><b>Susan M. Anderson</b>                             | 27 | Clinical Processing and Reporting   |
| <b>Susan Schwartz</b><br><b>R. George</b><br><b>J. Owens</b><br><b>J. Edson</b> | 33 | A Clinical Database Management System   |
| <b>Richard V. Cassidy</b>   | 43 | Standard Tables and Prompting Systems   |
| <b>Daniel M. Wildman</b>  | 49 | Enhancing NDAs with Graphics:<br>An Integrated System for Production and<br>Presentation Graphics |
| <b>Gene Averkin</b><br><b>Bonnie M. Beaver</b>                                  | 67 | Quality Assurance in Clinical Data<br>Management  |
| <b>Thomas W. Teal</b><br><b>Stephen J. Kopko</b>                                | 71 | Clinical Data Processing –<br>A Management Perspective  |
| <b>Thomas R. Hoffman</b><br><b>Judith Burns</b><br><b>Leon T. Hairie</b>        | 81 | THECIS – The Clinical Information<br>System   |
| <b>Eric S. Herbel</b>   | 89 | Integrated Clinical Research Support  |
-

## CONTENTS

- |  |     |  |
|--|-----|--|
| <b>Yvonne C. Martin</b><br><b>Ki H. Kim</b>  | 95  | Application of Theoretical Drug Design Methodology to a Series of Diuretics                              |
| <b>Corwin Hansch</b>   | 115 | On the State of QSAR   |
| <b>Paul N. Craig</b>   | 123 | QSAR—Origins and Present Status: A Historical Perspective  |
| <b>Gary G. Koch</b><br><b>William A. Sollecito</b>   | 131 | Statistical Considerations in the Design, Analysis, and Interpretation of Comparative Clinical Studies   |
| <b>Raymond E. Carhart</b>  | 153 | MRIDIR—A System for Integrating Research Databases   |
| <b>Graham M. Smith</b><br><b>David G. Hangauer</b><br><b>Joseph D. Andose</b><br><b>Bruce L. Bush</b><br><b>Eugene M. Fluder</b><br><b>Peter Gund</b><br><b>Eugene F. McIntyre</b> | 167 | Intermolecular Modeling Methods in Drug Design/Modeling the Mechanism of Peptide Cleavage by Thermolysin |
| <b>W. Jeffrey Howe</b>   | 179 | Intermediary-Free Substructure Searching   |
| <b>Donald G. Vidt</b>  | 185 | Comparative Clinical Trials—A Clinical Perspective   |
| <b>D. W. Taylor</b>  | 189 | Inspection of Computer-Supported Toxicological Data Submitted to the FDA                                 |

## CONTENTS

- Raymond L. Herman** 195 Introduction
- 197 Listing of Speakers, Workshop  
Leaders, and Committee Members

*OVERVIEW OF DRUG-  
ASSOCIATION ASSESSMENTS*

- Jan Venulet** 199 Aspects of Standardization as Applied  
to the Assessment of Drug-Event  
Associations
- William B. Freilich** 211 Legal Perspectives in Causality  
Assessment
- Alvan R. Feinstein** 219 Theoretical Perspectives in Causality  
Assessment
- M. N. G. Dukes** 227 The Uses of Causality Assessment
- Judith K. Jones** 233 Uses of Drug-Event Assessment
- Nelson S. Irey** 241 Case Report Methods for Assessing  
Causality
- Samuel Shapiro** 251 Problems in the Detection and  
Quantification of Adverse Drug  
Reactions

*APPLICATION OF METHODS*

- Judith K. Jones** 255 Introduction of Reference Case

*REGULATORY METHODS*

- Wayne Turner** 259 The Food and Drug Administration  
Algorithm
- Bengt-Erik Wiholm** 267 The Swedish Drug-Event Assessment  
Method
- Maurice L. Mashford** 271 The Australian Method of Drug-Event  
Assessment

*(Contents continued)**CLINICAL METHODS*

- Bernard Begaud** 275 Standardized Assessment of Adverse Drug Reactions: The Method Used in France
- Michael S. Kramer** 283 The Yale Algorithm  
**Tom A. Hutchinson**
- Michael Weintraub** 293 The General Clinical Pharmacology "Bias Elimination" Method

*INDUSTRIAL METHODS*

- Winifred M. Castle** 297 Assessment of Causality in Industrial Settings
- Alessandro Emanuelli** 303 A Simple Algorithm for Assessing Causality of Adverse Reactions
- Myles Stephens** 307 Assessment of Causality in Industrial Settings
- Jan Venulet** 315 The Ciba-Geigy Approach to Causality
- Judith K. Jones** 319 Summary of Applications  
**Michael Dreis**  
**Kay C. Pearson**
- David A. Lane** 323 A Probabilist's View of Causality Assessment
- Judith K. Jones** 331 Epilogue
- 339 Appendix A: Other Clinical Cases
- 349 Appendix B: References
- 353 Index to Volume 18, 1984

# Author Index Volume 18, 1984

Anderson SM, 27  
Andose JD, 167  
Averkin G, 67

Beaver BM, 67  
Begaud B, 275  
Bernd CL, 3  
Burns J, 81  
Bush BL, 167

Carhart RE, 153  
Carty P, 1  
Cassidy RV, 43  
Castle WM, 297  
Craig PN, 123

Dreis M, 319  
Dukes, MNG, 227

Edson J, 33  
Ehrlich S, 25  
Emanueli A, 303

Feinstein, AR, 219  
Fluder EM, 167  
Freilich WB, 211

Gandy LJ, 27  
George R, 33  
Gund P, 167

Hairie LT, 81  
Hangauer DG, 167  
Hansch C, 115  
Herbel ES, 89  
Herman RL, 195  
Hoffman TR, 81  
Howe WJ, 179  
Hutchinson TA, 283

Irey NS, 241

Jones JK, 233, 255,  
319, 331

Kim KH, 95  
Koch GG, 131  
Kopko SJ, 71  
Kowitt L, 9  
Kramer MS, 283

Lambros C, 19  
Lane DA, 323

Marlin RL, 9  
Martin YC, 95  
Mashford ML, 271  
McIntyre EF, 167

Owens J, 33

Pearson KC, 319

Schwartz S, 33  
Shapiro S, 251  
Smith GM, 167  
Sollecito WA, 131  
Steger D, 15  
Stephens M, 307

Taylor DW, 189  
Teal TW, 71  
Turner W, 259

Venulet J, 199, 315  
Vidt DG, 185

Weintraub M, 293  
Wiholm B-E, 267  
Wildman DM, 49

VOL.  
18  
1984